Company News
-
Mar 29, 2022Clover Reports Full Year 2021 Financial Results
-
Mar 17, 2022Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster
-
Feb 24, 2022Clover Selected for Inclusion on the Hang Seng Composite Index
-
Feb 14, 2022Clover Provides Corporate Update and 2022 Priorities
-
Feb 1, 2022Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
-
Jan 21, 2022Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet
-
Jan 5, 2022Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA
-
Jan 5, 2022Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai
-
Dec 9, 2021Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis
-
Dec 7, 2021Clover Signs COVID-19 Vaccine Supply Agreement with UNICEF
-
Nov 26, 2021Clover’s COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial
-
Nov 18, 2021Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a Booster
-
Nov 4, 2021Clover Biopharmaceuticals Announces Offer Price and Allotment Results of the Global Offering
-
Sep 22, 2021Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
-
Sep 10, 2021Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
-
Jul 6, 2021Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate
-
Jun 30, 2021Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility
-
Jun 30, 2021Clover and Dynavax Announce Commercial Supply Agreement of Dynavax’s CpG 1018 Adjuvant for Clover’s COVID-19 Vaccine Candidate
-
May 18, 2021Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
-
Mar 24, 2021Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate